Nuvation Bio Inc 税率 % : -0.00% (2023年12月 最新)
Nuvation Bio Inc税率 %(Tax Rate %)的相关内容及计算方法如下:
税率 % 由 -1 * 所得税费用 除以该公司的 利润总额 而得,通常以百分比形式表示。截至2023年12月, Nuvation Bio Inc 过去一季度 所得税费用 为 $ -0.00, 过去一季度 利润总额 为 $ -13.79,所以 Nuvation Bio Inc 过去一季度 的 税率 % 为 -0.00%。
点击上方“历史数据”快速查看Nuvation Bio Inc 税率 %的历史走势;
点击上方“解释说明”快速查看关于Nuvation Bio Inc 税率 %的详细说明;
点击上方“相关词条”快速查看与税率 %相关的其他指标。
Nuvation Bio Inc 税率 % (NUVB.WS 税率 %) 历史数据
Nuvation Bio Inc 税率 %的历史年度,季度/半年度走势如下:
Nuvation Bio Inc 税率 % 年度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
税率 % | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nuvation Bio Inc 税率 % 季度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
税率 % | - | - | - | - | - | - | - | - | - | - |
Nuvation Bio Inc 税率 % (NUVB.WS 税率 %) 计算方法
截至2023年12月,Nuvation Bio Inc过去一年的税率 %为:
截至2023年12月,Nuvation Bio Inc 过去一季度 的税率 %为:
Nuvation Bio Inc 税率 % (NUVB.WS 税率 %) 相关词条
感谢查看价值大师中文站为您提供的Nuvation Bio Inc税率 %的详细介绍,请点击以下链接查看与Nuvation Bio Inc税率 %相关的其他词条:
Nuvation Bio Inc (NUVB.WS) 公司简介
一级行业:医疗保健
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).